At least 2 million people get an antibiotic-resistant infection each year in the United States and at least 23,000 people die, according to the Centers for Disease Control and Prevention (CDC). It can often take several days to get results under the current standard of care for diagnosing bloodstream infections caused by antimicrobial-resistant pathogens, so antibiotics may be prescribed before it is known whether the strain is resistant to that treatment. The Antibiotics Resistance (ABR) panel developed by AIM Labs, is designed to expedite the right diagnosis, so patients can get targeted treatment sooner. A faster diagnosis also can cut down on the unnecessary use of antimicrobial drugs.